Curetis to Report its Half-Year Results 2016 on August 19, 2016
(Thomson Reuters ONE) -
Curetis /
Curetis to Report its Half-Year Results 2016 on August 19, 2016
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
- Company will host earnings conference call and webcast
Amsterdam, the Netherlands and Holzgerlingen, Germany, August 01, 2016 --
Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a
developer of next-level molecular diagnostic solutions, today announced that it
will publish its financial results for the first six months ended on June
30, 2016, on August 19, 2016. In addition, the Company will host a public
earnings conference call and webcast on August 19, 2016, at 03:00 pm CET /
09:00 am EST to present the H1 2016 financial results, highlight the most
important events and provide an outlook for the second half of 2016 and beyond.
The conference call will be supplemented by a presentation, which can be
accessed during the call at http://www.curetis.com/en/investors/financial-
reports-and-conferences/financial-reports.html through the participants'
passcode curetis0816. The live webcast and a replay will be available at
http://curetis190816-live.audio-webcast.com.
To access the call, please dial the following numbers using the passcode
93120684#
Germany: +49 692 222 290 43
UK: +44 203 009 2452
US: +1 855 402 7766
For further international dial-in numbers, please open the following link:
http://events.arkadin.com/ev/docs/International Access Numbers_
UKFELBRI1_SU7.pdf
The full half-year financial report 2016 will be available as of August
19, 2016, at http://www.curetis.com/en/investors/financial-reports-and-
conferences/financial-reports.html
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million. The company
is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as well as several
international distribution agreements covering many countries across Europe, the
Middle East and Asia.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
20160801_PR_EN:
http://hugin.info/171382/R/2032167/756444.pdf
Curetis_Logo:
http://hugin.info/171382/R/2032167/756446.jpg
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Curetis via GlobeNewswire
[HUG#2032167]
Unternehmensinformation / Kurzprofil:
Datum: 01.08.2016 - 08:40 Uhr
Sprache: Deutsch
News-ID 486457
Anzahl Zeichen: 6642
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 241 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis to Report its Half-Year Results 2016 on August 19, 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
